SynthesisJournal of human nutrition and dietetics : the official journal of the British Dietetic Association2026
Avoidant-Restrictive Food Intake Disorder in Patients With Gastrointestinal Disorders: A Systematic Review.
Synthesis in Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAvoidant-restrictive food intake disorder (ARFID) is an eating disorder diagnosis implemented with DSM-5 in 2013. Elevated risk for ARFID in patients with gastrointestinal disorders is suggested. This systematic review explored (1) methods used to identify patients with gastrointestinal disorders and comorbid ARFID and (2) their clinical characteristics.
methodsFollowing the PRISMA guidelines, Medline/PubMed, Embase, PsycInfo and CINAHL were searched for studies from January 2000 to December 2025 and a narrative analysis of the systematically extracted data was performed.
resultsTwenty-three studies with a total of 6211 participants were included. Studies were primarily observational with retrospective chart reviews or self-reported surveys. Twenty studies were conducted in tertiary gastroenterology clinics, primarily covering disorders of gut-brain interaction. Four studies focused on paediatric populations, 18 on adults and one included both. Participants were predominantly female, aged 6-90 years. ARFID case identification was heterogeneous regarding both data collection method, application of diagnostic criteria and diagnostic tool. ARFID symptoms were most consistently reported, with fear of aversive consequences, such as fear of abdominal pain, nausea or vomiting, being the most dominant. The negative consequences of ARFID symptoms were less consistently described.
conclusionLiterature on ARFID in gastrointestinal populations has increased in recent years. However, inconsistent identification of ARFID cases may lead to an overestimation of ARFID prevalence among patients with gastrointestinal disorders. Longitudinal studies with full diagnostic criteria applied are needed to better understand the prevalence and presentation of ARFID in gastrointestinal populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.